1. Alderson K, Holds JB, Anderson RL. Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology 1991; 41(11): 1800–1805.
2. Altaweel W, Jednack R, Bilodeau C et al. Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. J Urol 2006; 175(3 Pt 1): 1102–1105.
3. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor – which is the main mechanism of action. Eur Urol 2003; 43(1): 1–5.
4. Angaut-Petit D, Molgo J, Comella JX et al. Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features. Neuroscience 1990; 37(3): 799–808.
5. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006; 49(4): 644–650.
6. Atiemo H, Wynes J, Chuo J et al. Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model. Urology 2005; 65(3): 622–626.
7. Apostolidis A, Popat R, Yiangou Y et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174(3): 977-982; discussion 982–983.
8. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005; 26(5): 785–793.
9. Basbaum AI, Jessell TM. The perception of pain. In: Kandel ER, Schwartz JH, Jessell TM (eds). Principles of Neural Science. 4. ed. New York: McGraw Hill 2000: 472–491.
10. Bayliss M, Wu C, Newgreen D et al. A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle, from stable, unstable and obstructed bladders. J Urol 1999; 162(5): 1833–1839.
11. Birder LA, Nakamura Y, Kiss S et al. Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci 2002; 5(9): 856–860.
12. Borodic GE, Mills L, Joseph M. Botulinum A toxin for the treatment of adult-onset spasmodic torticollis. Plast Reconstr Surg 1991; 87(2): 285–289.
13. Borodic GE, Ferrante R. Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol 1992; 12(2): 121–127.
14. Brin MF, Fahn S, Moskowitz C et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol 1988; 50: 599–608.
15. Chancellor MB, O'Leary M, Erickson J et al. Successful use of bladder botulinum toxin injection to treat refractory overactive bladder [abstract DP50]. 98th Annual Meeting of the American Urological Association 2003, Chicago, IL, USA.
16. Chu FM, Dmochowski R. Pathophysiology of overactive bladder. Am J Med 2006; 119(3 Suppl 1): 3–8.
17. Chuang YC, Yoshimura N, Huang CC et al. Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 2004; 172(4 Pt 1): 1529–1532.
18. Coletti Moja M, Dimanico U, Mongini T et al. Acute neuromuscular failure related to long-term botulinum toxin therapy. Eur Neurol 2004; 51(3): 181–183.
19. Comperat E, Reitz A, Delcourt A et al. Histologic features in the urinary bladder wall affected from neurogenic overactivity – a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 2006; 50(5): 1058–1064.
20. Cortright DN, Szallasi A. Biochemical pharmacology of the vanilloid receptor TRPV1. Eur J Biochem 2004; 271(10): 1814–1819.
21. De Paiva A, Meunier FA, Molgo J et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999; 96(6): 3200–3205.
22. Ferguson DR, Kennedy I, Burton TJ. ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes – a possible sensory mechanism? J Physiol 1997; 505 (Pt 2): 503–511.
23. Ferguson DR. Urothelial function. BJU Int 1999; 84(3): 235–242.
24. Filippi GM, Errico P, Santarelli R et al. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993; 113(3): 400–404.
25. Ford AP, Gever JR, Nunn PA et al. Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br J Pharmacol 2006; 147(Suppl 2): 132–143.
26. Foster KA. The analgesic potential of clostridial neurotoxin derivatives. Expert Opin Investig Drugs 2004; 13(11): 1437–1443.
27. Giannantoni A, Nardicchi V, Di Stasi SM et al. Botulinum A toxin intravesical injections reduce nerve growth factor bladder tissue content in patients affected by neurogenic detrusor overactivity [abstract 221]. International Continence Society 2005, Montreal, Canada.
28. Giannantoni A, Di Stasi SM, Nardicchi V et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006; 175(6): 2341–2344.
29. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005; 47(5): 653–659.
30. Haferkamp A, Schurch B, Reitz A et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol 2004; 46(6): 784–791.
31. Harris CP, Alderson K, Nebeker J et al. Histologic features of human orbicularis oculi treated with botulinum A toxin. Arch Ophthalmol 1991; 109(3): 393– 395.
32. Hawthorn MH, Chapple CR, Cock M et al. Urothelium-derived inhibitory factor(s) influence detrusor muscle contractility in vitro. Br J Pharmacol 2000; 129: 416–419.
33. Holman ME, Spitzer NC. Action of botulinum toxin on transmission from sympathetic nerves to the vas deferens. Br J Pharmacol 1973; 47(2): 431–433.
34. Ishikawa H, Mitsui Y, Yoshitomi T et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Nippon Ganka Gakkai Zasshi 2001; 105(4): 218.
35. Juzans P, Comella JX, Molgo J et al. Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle. Neuromuscul Disord 1996; 6(3): 177–185.
36. Kessler TM, Danuser H, Schumacher M et al. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005; 24(3): 231–236.
37. Khera M, Somogyi GT, Kiss S et al. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004; 45(7): 987–993.
38. Kim HJ, Seo K, Yum KW et al. Effects of botulinum toxin type A on the superior cervical ganglia in rabbits. Auton Neurosci 2002; 102(1-2): 8.
39. Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 2005; 66(1): 94–98.
40. MacKenzie I, Burnstock G, Dolly JO. The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 1982; 7(4): 997–1006.
41. Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005; 20(5): 592–597.
42. Meunier FA, Schiavo G, Molgo J. Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris 2002; 96(1-2): 105–113.
43. Modugno N, Priori A, Berardelli A et al. Botulinum toxin restores presynaptic inhibition of group Ia afferents in patients with essential tremor. Muscle Nerve 1998; 21(12):1701–1705.
44. Morenilla-Palao C, Planells-Cases R, Garcia-Sanz N et al. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 2004; 279(24): 25665–25672.
45. Morris JL, Jobling P, Gibbins IL. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol 2001; 281(5): H2124.
46. O'Reilly BA, Kosaka AH, Knight GF et al. P2X receptors and their role in female idiopathic detrusor instability. J Urol 2002; 167(1): 157–164.
47. Pasricha PJ, Ravich WJ, Kalloo AN. Effects of intrasphincteric botulinum toxin on the lower esophageal sphincter in piglets. Gastroenterology 1993; 105(4): 1045–1049.
48. Paukert M, Osteroth R, Geisler HS et al. Inflammatory mediators potentiate ATP-gated channels through the P2X(3) subunit. J Biol Chem 2001; 276(24): 21077–21082.
49. Popat R, Apostolidis A, Kalsi V et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005; 174(3): 984–989.
50. Rapp DE, Turk KW, Bales GT et al. Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 2006; 175(3 Pt 1): 1138–1142.
51. Relja M, Telarovic S. Botulinum toxin type-A and pain responsiveness in cervical dystonia: A dose response study. Movement Disorders 2005; 20: S10.
52. Rosales RL, Arimura K, Takenaga S et al. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996; 19(4): 488–496.
53. Schulte-Baukloh H, Weiss C, Stolze T et al. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 2005; 66(1): 82–87.
54. Schulte-Baukloh H, Knispel HH, Stolze T et al. Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 2005; 66(4): 865-870; discussion 870.
55. Schurch B, de Seze M, Denys P et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005; 174(1): 196–200.
56. Simpson LL. The action of botulinal toxin. Rev Infect Dis 1979; 1(4): 656–662.
57. Smith CP, Franks ME, McNeil BK et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003a; 169(5): 1896.
58. Smith CP, Boone TB, de Groat WC et al. Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull 2003b; 61: 165.
59. Smith CP, Nishiguchi J, O'Leary M et al. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 2005; 65(1): 37–41.
60. Somogyi GT, Zernova GV, Yoshiyama M et al. Frequency dependence of muscarinic facilitation of transmitter release in urinary bladder strips from neurally intact or chronic spinal cord transected rats. Br J Pharmacol 1998; 125(2): 241–246.
61. Somogyi GT, Tanowitz M, Zernova G et al. M1 muscarinic receptor-induced facilitation of ACh and noradrenaline release in the rat bladder is mediated by protein kinase C. J Physiol 1996; 496(Pt 1): 245–254.
62. Spencer RF, McNeer KW. Botulinum toxin paralysis of adult monkey extraocular muscle. Structural alterations in orbital, singly innervated muscle fibers. Arch Ophthalmol 1987; 105(12): 1703–1711.
63. Sperlagh B, Vizi ES. Is the neuronal ATP release from guinea-pig vas deferens subject to alpha 2-adrenoceptor-mediated modulation? Neuroscience 1992; 51(1): 203–209.
64. Steers WD, Tuttle JB. Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol 2006; 3(2): 101–110.
65. Sun Y, Keay S, De Deyne PG et al. Augmented stretch activated adenosine triphosphate release from bladder uroepithelial cells in patients with interstitial cystitis. J Urol 2001; 166(5): 1951–1956.
66. Tarsy D, First ER. Painful cervical dystonia: clinical features and response to treatment with botulinum toxin. Mov Disord 1999; 14(6): 1043–1045.
67. Thesleff S, Molgo J, Tagerud S. Trophic interrelations at the neuromuscular junction as revealed by the use of botulinal neurotoxins. J Physiol (Paris) 1990; 84(2): 167–173.
68. Todorov LD, Mihaylova-Todorova S, Craviso GL et al. Evidence for the differential release of the cotransmitters ATP and noradrenaline from sympathetic nerves of the guinea-pig vas deferens. J Physiol 1996; 496(Pt 3): 731–748.
69. Tong YC, Hung YC, Shinozuka K et al. Evidence of adenosine 5'-triphosphate release from nerve and P2x-purinoceptor mediated contraction during electrical stimulation of rat urinary bladder smooth muscle. J Urol 1997; 158(5): 1973–1977.
70. Tsui JK, Fross RD, Calne S et al. Local treatment of spasmodic torticollis with botulinum toxin. Can J Neurol Sci 1987; 14(Suppl 3): 533–535.
71. Van Putten MJ, Padberg M, Tavy DL. In vivo analysis of end-plate noise of human extensor digitorum brevis muscle after intramuscularly injected botulinum toxin type A. Muscle Nerve 2002; 26(6): 784–790.
72. Wakabayashi Y, Kojima Y, Makiura Y et al. Acetylcholinesterase positive axons in the mucosa of urinary bladder of adult cats: retrograde tracing and degeneration studies. Histol Histopathol 1995; 10: 523–530.
73. Zubrzycka M, Janecka A. Substance P: transmitter of nociception (Minireview). Endocr Regul 2000; 34(4): 195–201.